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Context. Symptom control research in patients with advanced cancer is not common. This may be the result of a belief that
this research is unethical, not practical, or that patients are not interested. However, the experiences of cancer patients who
have actually taken part in symptom control research near the end of life have never been detailed.
Objectives. The objective was to explore the experiences of patients with advanced cancer who had taken part in symptom
control trials.
Methods. A prospective two-center study was undertaken using grounded theory methodology. Theoretical sampling was
used to recruit patients from one of two double-blind, randomized, placebo-controlled trials studying novel analgesic agents
for cancer-related pain. Participants completed one semistructured interview. Recruitment and interviewing continued until
data saturation was achieved.
Results. Twenty-one participants were recruited. Fifteen (71%) weremale, with amean age of 62 years. Key themes identified
included reasons for trial participation, participants’ interactions with the trial staff, and participants’ responses to the effect the
trial had on their pain. In general, participants regarded taking part in a clinical trial as a positive experience, and potentially
improving overall well-being. Crucially, this was not related to whether there had been an improvement in symptoms.
Conclusion. The findings provide grounds for optimism that patients with advanced cancer may benefit from taking part in
symptom control trials, supporting the paradigm that participation in symptom control research should be encouraged in this
population. J Pain SymptomManage 2015;50:642e649. 2015 The Authors. Published by Elsevier Inc. on behalf of American Academy
of Hospice and Palliative Medicine. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Patients with an advanced life-limiting illness such as
cancer describe multiple symptoms including pain,
fatigue, nausea, and breathlessness.1 The fact that inci-
dence and prevalence levels remain high indicates that
these symptoms are not always optimally managed.
One of the main reasons for this is the lack of an
evidence base for the treatment of symptoms.
Conducting research in these patients has tradition-
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a consequence, there remains a paucity of evidence
for treatment of common symptoms. There is a clear
need to improve the care of patients with life-
limiting illness through robust, meaningful, and
appropriate research.2,3
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sionals, including those in palliative care, to encourage
patients to participate in palliative care research, espe-
cially clinical trials, with paternalistic assumptionsRoad, Edinburgh, EH4 2XR, United Kingdom. E-mail:
tommiddlemiss@hotmail.com
Accepted for publication: May 19, 2015.
0885-3924
http://dx.doi.org/10.1016/j.jpainsymman.2015.05.009
Vol. 50 No. 5 November 2015 643Cancer Patients Benefit from Symptom Researchregarding vulnerability and cause of undue patient
distress as common themes.4 The concept of a placebo
arm can be of particular concern to many health pro-
fessionals when ‘‘standard’’ treatments are available,
even though this argumentmay be flawed when consid-
ering that the evidence for comparative therapies may
be based on anecdotal evidence alone.5 Additionally,
research proposals may be met with resistance from
ethics committees and health care practitioners alike,
with documented issues including concerns regarding
data protection, unsolicited contacting of patients,
choice of terminology to prevent distress to patients,
a view that dying patients should not be troubled by
research, poor understanding of methods used in
palliative care research, and a desire to prevent ‘‘uneth-
ical research.’’6e9
Conversely, previous studies have suggested that
patients with advanced cancer want to participate in
palliative care research. However, these studies asked
patients about their attitudes to hypothetical research
studies.10,11 Very little is known about the experiences
of patients who have actually participated in symptom
control trials. The aim of this novel piece of research
was to examine the experiences and attitudes of
patients with advanced cancer who took part in symp-
tom control trials.Methods
A prospective, two-center, qualitative study was un-
dertaken using grounded theory methodology.12e14
Ethical approval was obtained for this study (West of
Scotland Ethics Service, ref 09/s0703/104). Patients
were recruited from two regional cancer centers in
Scotland serving a population of approximately three
million people. Eligible patients met the following
criteria: a diagnosis of advanced cancer (defined as
metastatic and/or incurable), aged 18 years or older,
able to give written informed consent, and have partic-
ipated previously in one of two symptom control trials.
The symptom control trials were both double-blind,
placebo-controlled clinical trials studying ketamine
for neuropathic pain and pregabalin for bone pain as
novel analgesic agents (clinical trials: NCT01316744
and NCT00468845; see Appendix I for further details
of the clinical trials). Exclusion criteria were under
18 years of age, a cancer diagnosis with a potentially
curative outcome, and patients in the dying phase of
their illness. The choice of this final exclusion criteria
is discussed further on.
It is important to note that defining a palliative care
population is difficult as it is based on needs, not diag-
nosis nor stage of disease.15 Attempts have been made
to address this challenge.16 To study such a heteroge-
neous group would pose greater logistical challengesthan could be surmounted in one study. The decision
was made to study only patients with an advanced
cancer diagnosis. Therefore, when the term palliative
population is used herein, this refers to patients with
a diagnosis of advanced, metastatic, incurable cancer.Patient Sampling
The researcher/interviewer (T. M.) had no involve-
ment with the original clinical trials. The details of all
patients completing trial participation were made
available to him by trial staff. If patients were thought
to be suitable for interview, they were contacted either
by T. M. directly or by the research team to enquire
about their desire to take part in this study. Theoret-
ical sampling was used to select patients as the inter-
views proceeded. Patients were chosen to provide the
maximum diversity of experiences from the trials.17
Initially this sampling related to age, sex, trial, and
geographic location. Geographic location was impor-
tant as there were some different members of the trial
staff at the two recruitment sites. As the study pro-
gressed, the sampling was influenced by participants’
responses. Subsequent strategies involved approach-
ing patients with variable pain responses to the trial
(using pretrial and posttrial validated pain scores
that had been used in the trials), patients who had
contacted the researchers after the trial period had
ended, and those patients who had withdrawn from
the trials or who had been withdrawn from the trials
early for any reason. It was felt that this final group
of patients possibly would be negative cases that may
give an alternative view of their experiences of being
on the trial. All these patients were contacted; how-
ever, all declined to take part in this study. In compar-
ison to other palliative care research, patients enrolled
in the studied trials were largely still living indepen-
dently at home with an Eastern Cooperative Oncology
Group score of 1e2. Therefore, functional status was
not chosen as a sampling variable.Interview/Analysis Process
A semistructured interview using open questions
was carried out.18,19 Participants may have completed
the trial, withdrawn from the trial, or been withdrawn
from the trial. Every effort was made to interview
participants within two weeks of completing their trial
involvement. In some cases, the time between
completing the trial and interview was longer, for
example, at the start of the interview process when pa-
tients had completed the trial longer than two weeks
previously. The interviews were recorded, transcribed,
and a verbatim copy of the transcript was sent to the
participant, inviting him/her to comment or elabo-
rate on any points discussed.20 The intention of this
was to allow patients to elaborate or clarify any themes
Patients  screened  
n=103
Patients  eligible 
n=66
Patients  asked to participate
n=34
Reasons for non-inclusion
Similar demographics n=8
Unwell n=11
Withdrew from trial pre -
randomization n=9
Unknown n=1
Patients consented and interviewed
n=21
Reasons for non-inclusion
Declined n=5
Unwell n=3
Not available n=5
Fig. 1. This CONSORT diagram shows the patients who
were recruited into this study. It illustrates the total number
of patients who were eligible for the study and the reasons
why some were not contacted at different stages of the
recruitment process.
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study. However, no patients took up the opportunity
to contact the researchers for further discussion,
although some did comment that they had enjoyed
having a transcript of the interview.
Participants were given the choice of the interview
taking place in their home or in a hospital/research
setting. It was requested that participants be inter-
viewed alone; however, some participants did want to
have someone else present, and this request was
granted. Without trying to create a barrier between
interviewer and participant, all efforts were made to
ask that the participant answer all the questions, and
any comments made by anyone else were not analyzed.
In keeping with a grounded theory approach, data
analysis took place concurrently with the data gener-
ating process of interviewing.14 Known as constant
comparison, analysis of preliminary data influenced
subsequent participant selection and question genera-
tion, which in turn prompted further analysis of all
generated data. (Copies of the initial and final ques-
tion guide are listed in Appendix II.) T. M. undertook
line-by-line coding of the transcripts and initial data
analysis. This analysis and emerging themes were
then discussed with B. J. L. Analysis of the generated
data developed core categories and a central theory
that described the studied phenomenon. A clear audit
trail of this process was kept through memo writing
and field notes. Patients were recruited and inter-
viewed until a suitable degree of data saturation was
reached; in other words, until it was felt that no addi-
tional new data were likely to be generated from
further interviews.21
Constructivist grounded theory puts the role of the
researcher and their background at the forefront of
the research and its interpretation. To put the
researcher into the context of the research, T. M. is
a physician training to specialize in palliative medi-
cine. As this was not concealed from participants,
this may have had an impact on how participants
viewed T. M. (e.g., as part of the trial staff rather
than an independent researcher), the manner and
content of the responses they gave him and whether
they were fully able to share all their views. T. M.’s
background and status in the eyes of participants are
acknowledged factors that will have had an impact
on the research findings.Results
The screening and recruitment process are shown
in Fig. 1. During the period of study recruitment,
103 patients completed both trials. Of this number,
66 patients were eligible to be interviewed, 34 patients
were contacted, and 21 were interviewed. Reasons thatpatients were not contacted included those who were
too similar in sampling profile to those previously in-
terviewed, patients withdrawing from the trial before
taking any medication, and those who were too unwell
or dying to be felt appropriate to be contacted. Of the
patients that were contacted but not interviewed, rea-
sons included patient rejection, patients not replying
to the contact, and patients becoming too unwell be-
tween agreeing to take part and the interview date.
Participant demographics and disease characteris-
tics are shown in Table 1. Most participants were
male (n ¼ 15, 71%), and the mean age was 62.1 years.
The most common cancer type was prostate. Although
the intention was not to produce a representative
sample of eligible patients, comparison between those
interviewed and those eligible shows similarities akin
to representation.
The results are presented along the linear time
frame of trial participation, namely participant experi-
ences before starting the trial; participant experiences
during the trial; and patient reflections on being
involved in a trial. However, the themes that are
described are those that arose from participant re-
sponses and the subsequent data analysis. The central
theory of well-being, which links all aspects of partici-
pants’ trial participation, is also presented. For ease of
comprehension, colloquial language has been
amended.
Table 1
Comparison of Recruited and Eligible Patients’
Demographics
Demographics
Interviewed Patients
n ¼ 21
Eligible Patients
n ¼ 66
Gender
Male 15 (71%) 38 (58%)
Female 6 (29%) 28 (42%)
Age, yrs
mean 62.1 62.1
range 48e24 32e84
Diagnosis
Breast 6 (29%) 20 (30%)
Colorectal 0 (0%) 4 (6%)
Hematological 1 (5%) 6 (9%)
Lung 2 (10%) 9 (14%)
Prostate 7 (32%) 15 (23%)
Other 5 (24%) 12 (18%)
Trial
Ketamine Pain Study 7 (33%) 21 (32%)
Pregabalin Bone Trial 14 (67%) 45 (68%)
Trial site
Edinburgh 9 (43%) 30 (45%)
Glasgow 12 (57%) 36 (55%)
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The reasons for trial participation are shown in
Fig. 2. The awareness of the concept of clinical trials
varied among the patients studied. Some patients
had never heard of clinical trials. Other patients had
spoken to friends who had heard of clinical trials.
Some patients had been on other clinical trials in
the past or had known friends or relatives who had
taken part in clinical trials. Through the patient infor-
mation sheets and contact with the trial staff, partici-
pants subsequently felt well informed about their
specific trial. When considering whether to agree to
take part in a clinical trial, participants considered
what the trial would involve for them and in particular
weighed whether the trial would have a greater
perceived benefit than burden.
Female, 58 years, breast carcinoma: Ah, yes, I spoke
to my husband, my son, uh, my Dad (laughs), butReason
Taking P
the Tr
Pain
A desire to 
reduce their 
strong opioid
Other reasons 
for self-benefit
The dynamics 
of altruism
B
Benefit
OtherSelf-Benefit
Fig. 2. Reasons for trial participation. This figure illustrates the w
the clinical trial. Participants might have several of the reasons o
to others, and aspects that were not in the trial.eh, really it was a no brainer, it was eh, it was the
idea of pain relief is always a brilliant thing and
eh, um, I do agree with the principle of why they’re
looking at it.
Participants described positive reasons for taking
part in the trial within the context of someone benefit-
ting. This ‘‘someone’’ could be themselves, with moti-
vations for taking part including hopes for reducing
their pain, reducing the quantity of opioids they
were taking, or achieving a better structure to their
medications and care. However, someone else could
also benefit. Participants cited examples such as,
future patients or the researchers conducting the trials
benefitting from their participation. In the eyes of the
participant, the benefit from the trial did not have to
be solely for them.
Male, 48 years, pancreatic carcinoma: At the end of
the day, if you didn’t have people to try trials . I
wouldn’t be at this stage with my pain, so you’ve
got to, there has got to be guinea pigs along the
line somewhere.
Participants described three aspects of the trial
design that appeared favorable when considering
enrolling. These aspects were what the trials did not
contain rather than what they did an apparent lack
of excessive trial demands, a perceived lack of possible
side effects, and the lack of a lengthy trial period.
Male, 52, prostate carcinoma: I was persuaded a bit
more by the fact that it was only going to last for a
short time and it wasn’t going to really, cause me
any hassle, in the sense of having to go anywhere,
or go to the hospital, get ah . it was all going to
be done locally or on the end of a telephone.
When questioned about their view on being part of
a trial containing a placebo, participants had a good
understanding of the concept of placebo. Somes for 
art in 
ial
enefit to the 
researchers
Excessive 
burden of trial 
demands
High risk of 
side effects
Long trial 
duration
Aspects that Were 
not in the Trial
 to 
s
ide range of reasons why participants wanted to take part in
utlined. The reasons were grouped into self-benefit, benefits
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component of their trial and did not mind the possi-
bility that they may receive one.
T. M.: What did you think about the fact that you
might be on a placebo?
Female, 60, breast carcinoma: Well, not much, you
know, somebody’s got to be. It’s the only way they
can find out.
Some participants, however, showed a poor under-
standing of the concept of placebo by thinking that
the drugs they received throughout their own trial
could vary.
Male, 68, prostate carcinoma: Aye, some were, some
must have been real and some of them were dummy,
as far as, because the pain was not, I was not getting
great pain, know what I mean, some time.
This statement illustrates that despite the interac-
tion with the research staff and information sheets,
there is still the possibility of misunderstanding
regarding how or when the placebo is administered
to patients.
Participant Experiences During a Trial
The experiences of participants during the trial
period were mostly positive; ‘‘fascinating’’ as one
participant described it. One participant, who wanted
a better structure to his care, felt he had received just
that. Some participants described a very straightfor-
ward experience, largely devoid of positive or negative
incident.
Male, 72, prostate carcinoma: It was just all, get the
tablets, take the tablets, or hand them back or what-
ever and speak to the, speak to the girls. No there
was nothing out of the ordinary.
The main themes that participants described were
the impact of the trial on their pain and the interac-
tion with the trial staff.
Impact of the Trial on a Participant’s Pain. Some partic-
ipants described dying as a preferable option to
continuing to suffer their pretrial pain. Therefore,
the ‘‘relief beyond relief’’ at a good pain response was
clearly described. Some were stoical about a failure to
reduce their pain, whereas others described an under-
standable disappointment. However, this disappoint-
ment was not without the caveat that they knew what
the outcome might be when enrolling in the trial.
T. M.: What did you think after you’d started the
trial drug and there was no benefit?
Female, 58, breast carcinoma: I felt okay. I, I was not
disappointed or anything because I thought wellI’m doing it to help, it’s a drug and it’s a trial thing
and you’re helping other people and it did, it didn’t
bother me. Well, I would’ve been over the moon
obviously had it helped.Interaction with the Trial Staff. This was a continual
and key theme of the study. Some participants held
the trial staff in high regard, considering them ‘‘just
like a friend.’’ Participants would describe calling trial
doctors by their first names, trial nurses collecting
prescriptions on their behalf, and delivering on
promises. Participants felt that they were known
personally by the trial staff. A relationship based on
trust was built: ‘‘There’s no ‘next please.’’’ There was
a sense of security in being known and being able
to contact a member of the trial team at any time.
Conversely, other participants were more neutral,
complimenting the competency of the trial staff
without being effusive. This difference in perceived
interactions with the trial staff was explored closely
and is discussed later.
Negative Aspects of the Trial. No participants inter-
viewed stated that they did not like being on the trials.
A potential reason may be linked with the previously
discussed fact of not being able to recruit any negative
cases. However, some aspects of the trials were
described in a negative way by some patients. Negative
factors in a trial may lead to patient anxiety, which in
turn may lead to attrition rate or a negative experience
of trial participation. Negative factors that patients
described related to some of the trial questions, side
effects, the number of pills they were required to
take, and talking with someone new.
Some participants found that trial-related questions
regarding their pain were difficult to answer. For
some, this was quantifying their pain on a numerical
scale, whereas for others, it was choosing descriptive
words for their pain. Although two participants inter-
viewed had to withdraw from the trial because of
side effects, in general, the reported side effects of
hallucinations and somnolence were not described
with anxiety or irritation because the participants
found that their pain improved at the same time,
balancing the impact of the side effects. Some partic-
ipants noted that toward the end of a trial period,
the quantity of tablets they had to take was enough
to merit a comment when describing any negative
features of the trial.
Participant Thoughts About Being in a Trial
When participants reflected on taking part in these
symptom control trials, it was often within the context
of their pain. A participant who had a good pain
response was also typically positive about the trial.
Table 2
Examples of Positive and Negative Influences From a
Trial on a Patient’s Well-Being
Positive Influences Negative Influences
Pain reduction Taking too many pills
Altruistic acts Failure of the trial to reduce pain
Trial staff input Difficult questions to answer
The trial structure Side effects
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and subsequent underlying feelings of disappoint-
ment, their overall experience of the trial was still pos-
itive. Factors relating to this were the alternative
benefits that they took from the trial and the manner
in which they viewed the failure of the trial to reduce
their pain. Participants looked to other positives of the
trial, such as altruism, when their pain did not
decrease. They also viewed their participation in the
trial within the context of the potential of receiving
a placebo:
Male, 49, chronic myeloid leukemia: . that’s part
and parcel of these trials anyway. You know that
before you go into the trial.
Participants were generally happy to have taken part
in the trial. Some were happy to consider taking part
in another trial again, whereas others reported that
their body had had enough.Central Theory of Well-Being
Several questions permeated the interview findings
and data analysis. Why were some participants so pos-
itive about aspects of the trial, whereas others were
more neutral? Some participants were positive about
the trial even without a reduction in their pain.
What linked all the aspects of a participant’s experi-
ence of a clinical trial?
The answer, and the central theory grounded in the
data, lay in the impact on a participant’s well-being.
Well-being is a fluctuating equilibrium sensitive to in-
ternal and external influences and unique to each
participant. Given the uniqueness of well-being, like
pain, a comparison between individuals would be
meaningless. The impact of the trial on each individ-
ual’s well-being is unique. The affecting internal fac-
tors could be physical, emotional, or spiritual. The
external factors could be the interaction with others
or the loss of an activity, such as driving. When the
participant described his reduction in pain as ‘‘relief
beyond relief,’’ it was clear that this was having a pos-
itive impact on his well-being. The trial staff appeared
to be willing to do things that boosted or maintained
participants’ well-being rather than to diminish it.
Aspects of the trial, or care in general, could have a
negative impact on a participant’s well-being. Being
faced with eight new tablets on top of the usual thirty
tablets is one example (see Table 2 for examples of
positive and negative aspects of the trial on a partici-
pants’ well-being).The Individuality of Well-Being. Influences from
different aspects of the trial had different signifi-
cance for different individuals. For example, the fluc-
tuation in a participant’s pain state could increase ordecrease that participant’s well-being by different
amounts. Similarly, the benefit received from the
input of the trial staff may be greater in some partic-
ipants than others. When all the variable factors of
the trial are taken into account, the overall outcome
of the trial, whether positive or negative, is likely to
vary between individuals. This might suggest why
some participants found the trial to be a very positive
experience, whereas for others, it was something that
fitted into their daily routine without having much
impact.
The fluctuation of an individual’s well-being is
dynamic. The researchers did not think of it as
directly proportional to factors such as disease state
or physical condition. Instead, these factors play a
contributory role in the state of an individual’s well-
being. If the positive influences on an individual’s
well-being, perhaps emotional or spiritual, have a
greater effect than the negative influences, poten-
tially physical, it may explain why a participant who
had no reduction in pain was willing to continue to
take part in a clinical trial. It may be that an individ-
ual’s personality will influence the positive factors
that they take from a clinical trial. However, the total
influence from the clinical trial on a patient’s well-
being is finite. Everything that goes on in an individ-
ual’s life can increase or decrease their well-being.
The influencing factors from a clinical trial could
have a very small or very large impact on a person’s
overall well-being. The context of the trial in relation
to an individual’s overall well-being is beyond the
scope of this study. What has been considered is the
impact that being on a trial has on an individual’s
well-being.Discussion
This study provides valuable new information
regarding patients with advanced cancer participating
in symptom control trialsdan area with a hitherto
limited knowledge base. The trial process was found
at least to be straightforward and even enjoyable for
some patients. Although the principle motivation for
patients to participate in the trials was to reduce their
pain, altruism was a clear secondary reason. Lessons
for the design of future symptom control trials can
648 Vol. 50 No. 5 November 2015Middlemiss et al.be drawn from the positive comments relating to the
apparent simplicity and short duration of the trials,
the minimal hospital involvement, and the high
researcher contact.
The central theory of this study is that being in a
clinical trial has the potential to improve patients’
well-being, and this is echoed in the literature. Other
research has focused on the improvement of physical
symptoms to improve well-being.22 Although this
sentiment cannot be argued with, this study has shown
that even when physical symptoms do not improve,
well-being can still be improved by participation in a
clinical trial. The importance of the relationship be-
tween researcher and participant, which was found
in this trial, has been recognized by others in the
setting of advanced cancer. An improved ‘‘alliance’’
between patient and oncologist, as described by Trevi-
no,23 had a positive impact simultaneously on patient’s
well-being and treatment adherence, reinforcing the
argument that patients and researchers can both
benefit from a positive impact on a patient’s well-
being through a clinical trial. Although dealing with
life-prolonging treatment, rather than symptom man-
agement, Madsen24 found similarities in the clinical
trial experiences of patients with advanced breast can-
cer, particularly relating to the relationship with the
trial staff. ‘‘Positive psychological outcomes’’ are
described in the hospice setting when describing
health care professionals who invest in the patient
relationship.25 Furthermore, a review of well-being in
terminally ill patients included the themes of self-
awareness, having satisfying relationships with and
connections to others, and living with meaningdall
of which could be achieved during trial
participation.26
Excluding patients from study participation who
were in the ‘‘dying phase of their illness’’ runs the
risk of accusations of gatekeeping. The authors
acknowledge this and consider gatekeeping to be a
spectrum on which all must position themselves.
Although the experiences of patients who had taken
part in clinical trials were unknown, the researchers
chose to take a stronger view towards deciding on a de-
gree of gatekeeping. With the information discovered
in this study pointing toward positive experiences
from clinical trials and, by extrapolation, research in
general, those patients who may be closer to dying
could be considered for inclusion in studies such as
the one described.
Limitations
The present study has limitations. There is no
typical palliative care patient because of variables
such as performance status, diagnosis and prognosis.
As such, no clinical trials in palliative care patientswill cover this entire cohort. It is acknowledged that
the participants interviewed in this study were of a
higher performance status than a lot of palliative pa-
tients with further disease progression. In the same
manner, the studied trials were not particularly
arduous for the patients and this would have had
some impact on the manner in which they viewed
their particular trial and trials in general.
We endeavored to gather the widest ranges of partic-
ipant experiences, consistent with the trial populations
as a whole; however, we cannot ensure this was the case.
In the knowledge that some patients withdrew them-
selves from the trials, and refused to participate in
this study, some experiences of trial participation
have not been fully explored. Additionally, we inter-
viewed participants after they had finished a trial, and
thus their opinions may be limited by recall bias. Never-
theless, we are confident that the findings provide a
broad reflection of the range of the participants’
experiences.Conclusion
This is the first study examining the experiences of
patients with advanced cancer who have participated
in symptom control trials. Although patients may
derive an improvement in physical symptoms, trial
participation alone can improve well-being, making
the trial a therapeutic opportunity27 in and of itself.
These findings suggest that conducting symptom con-
trol research in patients with advanced cancer is
appropriate and may be beneficial, regardless of the
effect of the trial intervention. Although these find-
ings provide grounds for optimism, we welcome
further assessment and validation of our work. We pro-
pose that future work in this area should focus on
research for symptoms other than pain. Clearly, if
our findings are supported, this would have consider-
able implications for symptom control research in pa-
tients with life-limiting illness, challenging the
paradigm that conducting research in patients with
advanced cancer is inappropriate.Disclosures and Acknowledgments
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Clinical Trials
Pregabalin Bone Trialdthis was a randomized, double-blind trial of pregabalin vs. placebo in patients with
cancer-induced bone pain receiving palliative radiotherapy. After randomization, patients were allocated to pre-
gabalin or placebo for a period of 28 days. During this time, pregabalin/placebo was titrated to effect when either
pain improved or the maximum dose was reached.
Ketamine Pain Studydthis was a randomized, double-blind trial of ketamine vs. placebo in patients with
cancer-related neuropathic pain. After randomization, patients were allocated to ketamine or placebo for a
period of 14 days. During this time, ketamine/placebo was titrated to effect when either pain improved or the
maximum dose was reached. In patients whose pain improved, they continued in the study for a further
16 days (30 days in total).Appendix II
First Interview Schedule
Reasons for Participating
Can you tell me how you came to hear about the trial?
What was your initial reaction to the trial and how did you come to be involved?
What were your reasons for agreeing to take part in the trial?Areas that could be explored
Do you remember what your frame of mind was at the time of starting the trial (including mood and emotion)?
How were you coping with your acceptance of your disease at the time?
Was there any motivation to help others in taking part?
Did you feel that taking part would help improve your symptoms?
Could you tell me if taking part in the study affected your levels of hope?Experience of the Trial
What were your experiences of the trial?
How well did you understand what you were participating in?
Do you feel you were fully informed of the requirements of the trial?
Had you been involved in previous research/trials?
Did you have any negative experiences during the trial?Areas that could be explored
What were your experiences with the research staff (i.e., doctors and nurses)?
What impact did the trial have on your life?
Last Interview Schedule
What do you remember about the trial?
Did being on the trial change how you see yourself as a person?
How do you look back on the period of time when you were on the trial?
What happened after the trial finished?
How did you find the change after the contact with the trial staff ceased?
If no benefit, has the trial been a waste of your time?
Can you remember anything that occurred that you were not expecting during the trial?
What area of the clinical trial could be better for patients like you?
